Paper Details

  1. Home
  2. Paper Details

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells.

Author: GotohAkihiko, OkabeSeiichi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigates the potential of Vitamin K2 (VK2) to enhance the effects of asciminib, an ABL myristoyl pocket (STAMP) inhibitor, in treating chronic myeloid leukemia (CML). While VK2 has shown anticancer activity, its impact on asciminib's effectiveness is currently unknown.
Paper Details　
Original Abstract of the Article :
Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy. Vitamin K2 (VK2) is a crucial fat-soluble vitamin used to activate hepatic coagulation factors and treat osteoporosis. Although VK2 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478393/

データ提供：米国国立医学図書館（NLM）

Asciminib and Vitamin K2: A New Alliance in the Desert of Chronic Myelogenous Leukemia

This study takes us on a journey through the desert of chronic myelogenous leukemia (CML), a challenging hematologic malignancy. The authors investigate the potential synergy between asciminib, a specific ABL myristoyl pocket inhibitor, and vitamin K2, a fat-soluble vitamin with known anticancer activity. It's like exploring a vast desert, seeking new alliances to combat this disease.

Asciminib and Vitamin K2: A Promising Partnership in the Desert

The study explores the potential of combining asciminib and vitamin K2 to overcome resistance to ABL tyrosine kinase inhibitors (TKIs) in CML. It's like discovering a new partnership in the desert—a combination of forces that could lead to more effective treatment strategies. The authors suggest that vitamin K2 could potentially enhance the effects of asciminib, offering hope for patients who have developed resistance to traditional ABL TKIs.

Navigating CML Treatment: Seeking New Routes in the Desert

This study provides valuable insights into the potential of new treatment strategies for CML, particularly for patients who have developed resistance to TKIs. It's like finding a new path through a challenging desert—this research could lead to more effective and personalized treatment approaches for CML patients.

Dr. Camel's Conclusion

The combination of asciminib and vitamin K2 offers a potential breakthrough in the treatment of CML, particularly for patients who have developed resistance to traditional TKIs. This study, like a map guiding us through the desert of CML, highlights the importance of exploring new treatment strategies to overcome this challenging disease.
Date :
  1. Date Completed 2023-09-07
  2. Date Revised 2023-11-22
Further Info :

Pubmed ID

37670241

DOI: Digital Object Identifier

PMC10478393

Related Literature

Article Analysis
・Effects of asciminib・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.